119 related articles for article (PubMed ID: 20403587)
1. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study.
Rauf SM; Ismael M; Sahu KK; Suzuki A; Koyama M; Tsuboi H; Hatakeyama N; Endou A; Takaba H; Del Carpio CA; Kubo M; Miyamoto A
Comput Biol Med; 2010 May; 40(5):498-508. PubMed ID: 20403587
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.
Nikolova PV; Wong KB; DeDecker B; Henckel J; Fersht AR
EMBO J; 2000 Feb; 19(3):370-8. PubMed ID: 10654936
[TBL] [Abstract][Full Text] [Related]
4. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
[TBL] [Abstract][Full Text] [Related]
6. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
[TBL] [Abstract][Full Text] [Related]
7. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".
Friedler A; DeDecker BS; Freund SM; Blair C; Rüdiger S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):187-96. PubMed ID: 14741214
[TBL] [Abstract][Full Text] [Related]
8. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
Joerger AC; Ang HC; Veprintsev DB; Blair CM; Fersht AR
J Biol Chem; 2005 Apr; 280(16):16030-7. PubMed ID: 15703170
[TBL] [Abstract][Full Text] [Related]
9. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Wong KB; DeDecker BS; Freund SM; Proctor MR; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8438-42. PubMed ID: 10411893
[TBL] [Abstract][Full Text] [Related]
10. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ; Butler JS; Loh SN
J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
[TBL] [Abstract][Full Text] [Related]
11. Detection of mutant p53 using field-effect transistor biosensor.
Han SH; Kim SK; Park K; Yi SY; Park HJ; Lyu HK; Kim M; Chung BH
Anal Chim Acta; 2010 Apr; 665(1):79-83. PubMed ID: 20381694
[TBL] [Abstract][Full Text] [Related]
12. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
Trulson JA; Millhauser GL
Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
14. Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain.
Duan J; Nilsson L
Biochemistry; 2006 Jun; 45(24):7483-92. PubMed ID: 16768444
[TBL] [Abstract][Full Text] [Related]
15. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.
Butler JS; Loh SN
Biochemistry; 2003 Mar; 42(8):2396-403. PubMed ID: 12600206
[TBL] [Abstract][Full Text] [Related]
16. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
17. Microsecond molecular dynamics simulations reveal the allosteric regulatory mechanism of p53 R249S mutation in p53-associated liver cancer.
Liu X; Tian W; Cheng J; Li D; Liu T; Zhang L
Comput Biol Chem; 2020 Feb; 84():107194. PubMed ID: 31881526
[TBL] [Abstract][Full Text] [Related]
18. Sequence-specific interaction of a conformational domain of p53 with DNA.
Srinivasan R; Roth JA; Maxwell SA
Cancer Res; 1993 Nov; 53(22):5361-4. PubMed ID: 8221671
[TBL] [Abstract][Full Text] [Related]
19. Mutation scanning of the p53 tumor suppressor gene in renal and liver transplant patients in Hungary.
Sarvary E; Nagy P; Benjamin A; Szoke M; Remport A; Jansen J; Nemes B; Kobori L; Fehervari I; Sulyok B; Perner F; Varga M; Fazakas J; Lakatos M; Szabo M; Toth A; Járay J
Transplant Proc; 2005 Mar; 37(2):969-72. PubMed ID: 15848594
[TBL] [Abstract][Full Text] [Related]
20. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin.
De Grandis V; Bizzarri AR; Cannistraro S
J Mol Recognit; 2007; 20(4):215-26. PubMed ID: 17703463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
